Get started
CRISPR THERAPEUTICS AGCRISPR THERAPEUTICS AGCRISPR THERAPEUTICS AG

CRISPR THERAPEUTICS AG

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

CRSP/N trade ideas

Long (potential takeover, solid pipeline, tons of cash)- potential aim for takover (I suppose by VRTX ) . Company has 2.5B in cash, no debt with market cap about 4.5B$ (EV = 2.0 B) - solid pipeline and probably will be first who get FDA approval for commercial CRISPR product - got most of up front payment for milestones in CRISPR among competitors ( about 1b$ from Vertex and collaboration with Bayer). BEAM for example got only 300m$ in up front payment, NTLA even less. That means CRSP has enough cash for 4 years R&D without share offering and sustain global recession.
NASDAQ:CRSPLong
by Zacateca
CRISPR Therapeutic needs to break 83.46. This is a critical testCrispr has been moving up since the Morning star break out on 13th December. Its further progress hinges on breaking the 83.46 resistance. It has tried piercing this resistance twice but failed. The resistance line at 83.46 and the upward support channel formed since 14th December at $70.37 is intersecting 83.46 on 28th December and CRSP has to break out before that to make any further progress. Option strategies can be deployed to exploit the opportunity either way.
NASDAQ:CRSP
by ShareTreck
CRSPCRSP It's time to update the idea. The care turned out to be very deep, although this option of leaving for zone 77 was supposed. Now we have dropped out of the channel a little, we will count for an error, we are also holding on to the ema200 during the week, we have formed hidden divergences during the week, taking into account the potential of the company, the growth of xbi and the VRTX partner may be interesting. It may still come down and test the "trend", but we are already at a good level
NASDAQ:CRSP
by S0rt0
1
CRSP on a major weekly level. What's coming next? Today we will take a look at CRISPR Therapeutics. Which are the main technical elements we can see here? a) The price is against a major Support/Resistance level, working since 2018. The price reaction on these zones tends to provide solid insight into future movements. b) Let's assume the price bounces on the current zone; what can we expect? - A movement towards the descending trendline around 100.00. IF that happens, that would be a take-profit level for me. Why? Because we tend to observe corrections once the price reaches a major level. You don't want to be insight a sideways movement for 100 days c) Let's assume that the price breaks the current level and keeps falling. What can we expect? - A movement towards the ascending trendline around 50.00. That would be the next level where I would start thinking again about bullish reversals. d) I'm a position trader. What is the most relevant level right now to develop setups? -If that's your case, I want to see first a breakout of the descending trendline; IF that happens, I want to see a correction of around 50 days. IF that is the case, I will be interested in trading that breakout for the long term. However, at the moment, we are far away from that situation, and I would stay away from this chart for long-term setups. Thanks for reading! Feel free to share your view of this in the comments.
NASDAQ:CRSP
by ThinkingAntsOk
1
CRISPR BUY OR NOT TO BUY..?Third Quarter 2021 Financial Results • Cash Position: Cash, cash equivalents, and marketable securities were $2,477.4 million as of September 30, 2021, compared to $2,589.4 million as of June 30, 2021. The decrease in cash of $112.0 million was primarily driven by cash used in operating activities to support ongoing research and development of the Company’s clinical and pre-clinical programs. • Revenue: Total collaboration revenue was $0.3 million for the third quarter of 2021, compared to $0.1 million for the third quarter of 2020. Collaboration revenue primarily consisted of revenue recognized in connection with our collaboration agreements with Vertex. • R&D Expenses: R&D expenses were $105.3 million for the third quarter of 2021, compared to $71.0 million for the third quarter of 2020. The increase in expense was driven by the development activities supporting the advancement of the hemoglobinopathies program and wholly-owned immuno-oncology programs, as well as increased headcount and supporting facilities, related expenses. • G&A Expenses: General and administrative expenses were $24.4 million for the third quarter of 2021, compared to $21.5 million for the third quarter of 2020. The increase in general and administrative expenses for the year was primarily driven by headcount-related expenses. • Net Loss: Net loss was $127.2 million for the third quarter of 2021, compared to a net loss of $92.4 million for the third quarter of 2020. crisprtx.gcs-web.com MACD: BEARISH CROSS RSI: OVERSOLD VOLUME: LOW CURRENT SUPPORT @ 1.272 FIB 1.618 IS YOUR IMPULSE TARGET FOR A BREAK IN EITHER DIRECTION Puzzled on this one honestly, looks like it wants to go lower, but we'll see at the weekly close. Keep an eye on the SPY index. DYOR PRACTICE RISK MANAGEMENT GOOD LUCK
CAPITALCOM:CRSP
by BearManalow